Bristol-Myers Squibb Surges 76% in Trading Volume to 73rd Rank Amid Clinical Trial and Acquisition News

On April 23, 2025, Bristol's trading volume reached 11.63 billion, marking a significant increase of 76.01% compared to the previous day, placing it at the 73rd position in the day's stock market rankings.

Bristol-Myers Squibb has announced that it will be conducting a clinical trial for its new drug, BMS-986165, which is designed to treat a rare form of cancer. The trial will involve 500 patients and is expected to last for two years. The company has stated that the results of the trial will be crucial in determining the drug's efficacy and safety.

Bristol-Myers Squibb has also announced that it will be acquiring a biotechnology company, which specializes in the development of gene therapies. The acquisition is expected to strengthen Bristol-Myers Squibb's position in the gene therapy market and expand its product portfolio. The terms of the acquisition have not been disclosed.

Bristol-Myers Squibb has reported that its first-quarter earnings have exceeded analysts' expectations. The company's revenue for the quarter was $11.2 billion, up 10% from the same period last year. The company's net income for the quarter was $2.5 billion, up 15% from the same period last year. The company has attributed the strong performance to the success of its new drugs and the acquisition of a biotechnology company.